Sphera Funds Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Sphera Funds Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-15,833	Closed	-$4.68M	–	132
2018 Q1	$4.68M	Sell	15,833 -1,216	-7%	-$359K	0.71%	45
2017 Q4	$7.13M	Sell	17,049 -293	-2%	-$105K	0.84%	25
2017 Q3	$5.72M	Buy	17,342 +4,499	+35%	+$1.23M	0.82%	28
2017 Q2	$3.04M	Hold	12,843	–	–	0.52%	59
2017 Q1	$4.41M	Hold	12,843	–	–	0.86%	27
2016 Q4	$4.49M	Buy	12,843 +391	+3%	+$143K	1.14%	24
2016 Q3	$5M	Buy	12,452 +7,428	+148%	+$3.79M	0.81%	29
2016 Q2	$2.99M	Buy	5,024 +107	+2%	+$65K	0.78%	38
2016 Q1	$2.47M	Buy	+4,917	New	+$2.45M	0.54%	37
2015 Q1	–	Sell	-335	Closed	-$2.94M	–	170
2014 Q4	$2.94M	Sell	335 -78	-19%	-$453K	0.5%	65
2014 Q3	$1.94M	Buy	413 +80	+24%	+$423K	0.24%	88
2014 Q2	$2.4M	Buy	+333	New	+$1.67M	0.59%	42

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sphera Funds Management's EIGR Position: Q2 2018 in Review

Sphera Funds Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2018, closing a stake of 15,833 shares — an estimated $4.68M sold.

Sphera Funds Management first reported a position in EIGR in Q2 2014 and held it in 12 quarters. The position peaked at $7.13M in Q4 2017. 50 funds tracked by Wall St. Rank hold EIGR as of Q2 2018.

Sphera Funds Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Sphera Funds Management sold 15,833 Eiger BioPharmaceuticals, Inc. shares in Q2 2018, an estimated $4.68M.
Sphera Funds Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 12 quarters.
Sphera Funds Management's Eiger BioPharmaceuticals, Inc. position peaked at $7.13M in Q4 2017.
50 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2018.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.